medroxyprogesterone acetate + human menopausal gonadotropin

The combination of medroxyprogesterone acetate (MPA) and human menopausal gonadotropin (hMG) is the foundational regimen for the **Progestin-primed ovarian stimulation (PPOS)** protocol, pioneered by researchers at **Shanghai Ninth People's Hospital**. In this protocol, MPA is administered orally as a synthetic progestin to provide negative feedback on the hypothalamus-pituitary-ovarian axis, effectively suppressing premature luteinizing hormone (LH) surges during the follicular phase. Simultaneously, hMG (a purified extract containing both follicle-stimulating hormone and luteinizing hormone) is injected to stimulate the development of multiple ovarian follicles. This approach is particularly effective for patients with **polycystic ovary syndrome (PCOS)** and those undergoing 'freeze-all' IVF cycles, as the use of progestins prevents immediate embryo transfer by making the endometrium non-receptive, necessitating cryopreservation of embryos for future transfer.

Other names

MPA + hMGProgestin-primed ovarian stimulation protocolPPOS protocol